Ototoxicity from Furosemide
Furosemide carries a significant risk of ototoxicity, particularly with rapid IV administration, high doses (>6 mg/kg/day or >4 mg/min IV infusion rate), renal impairment, hypoproteinemia, or concurrent use with other ototoxic drugs like aminoglycosides—and this risk can be substantially mitigated through slow administration and careful monitoring. 1
Risk Factors and Mechanisms
The FDA label explicitly warns that furosemide ototoxicity is associated with several key factors 1:
- Rapid injection (most critical modifiable risk)
- Severe renal impairment (reduced drug clearance)
- Higher than recommended doses
- Hypoproteinemia (potentiates ototoxicity)
- Concomitant ototoxic drugs (aminoglycosides, ethacrynic acid, cisplatin)
The pathophysiology involves edema and cystic degeneration of the stria vascularis, with dose-dependent severity 2. When combined with aminoglycosides, furosemide increases cell membrane permeability in the inner ear, allowing the aminoglycoside to penetrate at higher concentrations and cause more severe damage 3.
Clinical Presentation
Ototoxicity manifests as:
- Tinnitus (often the earliest sign)
- Reversible or irreversible hearing impairment
- Deafness (in severe cases)
- Typically bilateral and can be rapidly progressive 1, 2
Unlike aminoglycosides, furosemide primarily affects cochlear function (hearing) rather than vestibular function 4.
Prevention Strategies
Dosing and Administration
For IV furosemide, use controlled infusion at ≤4 mg/min rather than bolus injection 1. This single intervention eliminated permanent hearing loss in a pediatric cardiac surgery cohort (17% to 0%) 5.
Limit high-dose therapy (>6 mg/kg/day) to ≤1 week duration and administer infusions over 5-30 minutes to avoid hearing loss 6.
Avoid exceeding 50 mcg/mL blood levels when possible 4.
Drug Interactions to Avoid
Do not combine furosemide with:
- Aminoglycosides (streptomycin, amikacin, kanamycin, gentamicin) except in life-threatening situations 7, 8, 1
- Ethacrynic acid (another loop diuretic) 1
- Cisplatin without dose reduction and positive fluid balance 1
The guidelines are explicit: streptomycin's ototoxicity risk "is increased with age or concomitant use of loop-inhibiting diuretics (furosemide, ethacrynic acid)" 7, 8. Similarly, increased ototoxicity risk exists with concurrent use of loop diuretics and aminoglycosides in non-tuberculous mycobacterial disease 9.
High-Risk Populations Requiring Extra Caution
- Elderly patients (>59 years)
- Renal insufficiency (reduced drug clearance)
- Hypoproteinemia (nephrotic syndrome, cirrhosis)
- Infants (particularly those with single-ventricle cardiac defects or chronic lung disease) 6, 10, 5
Monitoring Protocol
Baseline Assessment
- Audiogram (pure tone audiometry)
- Renal function (creatinine, BUN)
- Serum albumin (if hypoproteinemia suspected)
During Therapy
- Question patients monthly about auditory symptoms (tinnitus, hearing changes)
- Repeat audiometry if any symptoms develop 7, 8
- Monitor renal function regularly, as declining function increases ototoxicity risk 1
Ototoxicity on audiogram is defined as: ≥20 dB loss from baseline at any one frequency OR ≥10 dB loss at any two adjacent frequencies 9.
Post-Exposure
Consider final audiometry 2 months after discontinuation in high-risk patients 9.
Management of Established Ototoxicity
Immediately discontinue furosemide if ototoxicity develops 1.
Substitute alternative diuretics such as bumetanide (though it carries similar but potentially lower ototoxic risk) or thiazide diuretics combined with potassium-sparing agents 6, 4.
Refer to audiology for any patient with >15 dB hearing loss or symptomatic tinnitus for standard hearing loss interventions 11.
Critical Clinical Pitfalls
Rapid IV bolus administration is the most common preventable cause—always use slow infusion 1, 5
Assuming oral furosemide is safe—while less risky than IV, oral administration can still cause ototoxicity, especially at high doses or with concurrent ototoxic drugs 10, 4
Failing to recognize synergistic toxicity—ototoxicity can occur after just 5 days of gentamicin plus a single dose of furosemide 3
Overlooking hypoproteinemia—patients with nephrotic syndrome or cirrhosis have both weakened diuretic effect AND potentiated ototoxicity 1
Continuing therapy despite early symptoms—tinnitus is often the first warning sign and warrants immediate evaluation 12